General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Why Rivian Stock Investors Need Nerves of Steel Amid Mixed Outlook | news.google.com • |
The US Stock Market's Outlook: Further Gains in 2024 Mainly Dependent on Rate Cuts? | news.google.com • |
Salesforce Shares Plunge by Most Since 2008 After Weak Outlook | news.google.com • |
Nutanix Stock: Earnings Beat, While Revenue Outlook Misses. Shares Tumble | news.google.com • |
Salesforce Stock Plunges on Q1 Revenue Miss, Soft Outlook | news.google.com • |
Kohl’s Q1 Earnings: Revenue And Profit Miss, Outlook Cut, Stock Tumbles Why Department Store Chain Kohl's | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-15 | 2024-03 | -0.88 | -1.55 | -0.67 | -76.14% |
2024-02-14 | 2023-12 | -1 | -0.8 | 0.2 | 20.00% |
2023-12-22 | 2023-09 | -1 | -1 | N/A | N/A |
2023-08-14 | 2023-06 | -0.8 | -1.6 | -0.8 | -100.00% |
2023-05-15 | 2023-03 | -1.2 | -0.6 | 0.6 | 50.00% |
2023-02-14 | 2022-12 | -0.8 | -1.6 | -0.8 | -100.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-30 | Chardan Capital | Downgrade | Buy | Neutral |
2023-08-30 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2023-08-29 | Brookline Capital | Downgrade | Buy | Hold |
2023-08-29 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
2023-08-29 | BTIG | Downgrade | Buy | Neutral |
2023-08-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-04-19 | DAGNON TERRY | Chief Operating Officer | 653.06K | Sale |
2024-03-06 | EVANSON JEFF | Officer | 808.46K | Purchase |
2024-03-27 | HADDADIN YEZAN MUNTHER | Director | 5.05K | Purchase |
2022-10-04 | HILZINGER KURT J | Director | 473.12K | Purchase |
2021-04-19 | KENYON LAWRENCE A. | Chief Executive Officer | 18.93K | Purchase |
2022-10-06 | SUKHTIAN FAISAL GHIATH | Director | 68.00K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 9.22M | 16.04M | 3.54% |
2023-06-29 | Vanguard Group Inc | 6.15M | 10.70M | 2.36% |
2023-06-29 | State Street Corporation | 2.75M | 4.79M | 1.06% |
2023-06-29 | Geode Capital Management, LLC | 2.72M | 4.73M | 1.05% |
2023-06-29 | Northern Trust Corporation | 1.26M | 2.18M | 0.48% |
2023-06-29 | Nuveen Asset Management, LLC | 598.96K | 1.04M | 0.23% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.61M | 6.28M | 1.39% |
2023-08-30 | iShares Russell 2000 ETF | 3.58M | 815.24K | 1.37% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.45M | 2.52M | 0.56% |
2023-07-30 | Fidelity Small Cap Index Fund | 1.38M | 2.38M | 0.53% |
2023-08-30 | iShares Russell 2000 Growth ETF | 1.27M | 289.29K | 0.49% |
2023-05-30 | Fidelity Extended Market Index Fund | 519.75K | 779.62K | 0.20% |
Split | Date |
---|---|
1 : 20 | 2024-03-14 |
1 : 8 | 2019-03-18 |
Frank Chance is back. He is talking like he is worried…… he should be!
Derek Danial, you may want to get a broker to help you. Based on all your statements… I don't think you have a clue what's going on or how things are done. My advice is done go to deep on your first trades and maybe pick up some educational books on trading. Last tip: font listen to The Wiz, Waldo_III or Frank Chance. Clueless doesn't begin to describe their insight on stocks.
every short seller has a buyer, but every Buyer won’t have a seller
I am still buying and when you need me to cover your short gambling habit… I won't!!!! Call it tough love and a lesson about greed. The time of the short is quickly coming to an end.
Derick Danial, that is absolutely not how it work!
The more the shorts sell… the bigger the trap!
Why would anyone be selling???? Is there a reasonable explanation? Any ideas at all???
If you are hoingbto buy more.… now is the time!!!
You won't see OTLK this cheap ever again
Go shorts go!!! Im long and will not sell during the run away. The study is done approval is eminent approval. All debt is moved to stock…. So no loans to worry about and all the money secured for launch in $19billion market half already capture do to market patent exclusivity. If you have doubts on approval you didn't do your homework. FDA only asked for a reenactment of a National Eye Institute study done over a decade ago. The shorts are loading the market with a gluttony of shares they will never be able to cover. Yes they are driving price done for the moment but when the music stops the mad scramble will begin. Go shorts go! There are not enough shares to cover.
Randomized Controlled Trial
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
CATT Research Group et al. N Engl J Med. 2011.
Show details
Full text links
Cite
Abstract
Background: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data.
Methods: In a multicenter, single-blind, noninferiority trial, we randomly assigned 1208 patients with neovascular AMD to receive intravitreal injections of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation. The primary outcome was the mean change in visual acuity at 1 year, with a noninferiority limit of 5 letters on the eye chart.
Results: Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively. Bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab as needed was equivalent to monthly ranibizumab, although the comparison between bevacizumab as needed and monthly bevacizumab was inconclusive. The mean decrease in central retinal thickness was greater in the ranibizumab-monthly group (196 μm) than in the other groups (152 to 168 μm, P=0.03 by analysis of variance). Rates of death, myocardial infarction, and stroke were similar for patients receiving either bevacizumab or ranibizumab (P>0.20). The proportion of patients with serious systemic adverse events (primarily hospitalizations) was higher with bevacizumab than with ranibizumab (24.1% vs. 19.0%; risk ratio, 1.29; 95% confidence interval, 1.01 to 1.66), with excess events broadly distributed in disease categories not identified in previous studies as areas of concern.
Conclusions: At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule. Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly. Differences in rates of serious adverse events require further study. (Funded by the National Eye Institute; ClinicalTrials.gov number, NCT00593450.).
PubMed Disclaimer
Woody Walls you lost your money because you don't know what you are doing. Misery loves company quit trying to pull others down with your ignorance. The money is a the finish line of approval. You dropped out an sold to the Wiz, Frank Chance, Waldo_III and I ️animal
Studies. They took your money and are now laughing at you.
Frank Chance, you are a penny flipper with no understanding of how to make the big money. Based on your gambling disclosures, I believe you are still down money. The number of clown faces seem to mirror your loses.
Frank Chance, I told you not to climb into the barrel. How much are you down now! Don't be stubborn and lose it all. Close out your short sale. Don't say I didn't warn you
I love reading the penny flippers cry over their losses... Like its everyone else fault. Everyone but them.
David Price, in the future please do your homework before giving advice. Second, there is no reason not to get EMA approval and then FDA. There is no way you can know unless you are inside trading.
I ️animal studies, what a load of crap. It is clear that you have no background or experience in any part of how this works. It maybe best if you zip it and sit down.… pay attention and learn something.
Make the call: gutsy or stupid to short right now? personally, I’m cheering on the shorts but of course I’m long.
https://pubmed.ncbi.nlm.nih.gov/21526923/
If you have any doubts about EMA or FDA approval. Take a sneak peak of the outcome.
Frank Chance, Come on show us how it's done. Keep shorting OTLK. After all that talk you can't stop now. Keep SHORTING you can do it. Show us how smart you are. Dont be a disappointment keep shorting. Show us all the money you are going to make!!!!